FDA Inspection 1162967 — Diamond Institute For Infertility And Menopause
The FDA completed an inspection of Diamond Institute For Infertility And Menopause on Feb 23, 2022 in Millburn, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). 5 citations were issued during this inspection. Product area: Biologics.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Feb 23, 2022
- Fiscal Year
- 2022
- Product Type
- Biologics
- Project Area
- Vaccines and Allergenic Products
- Location
- Millburn, NJ (United States)
Citations
| ID | CFR | Description |
|---|---|---|
| 12213 | 21 CFR 1271.47(a) | Testing, screening, donor eligibility procedures |
| 12239 | 21 CFR 1271.55(b)(2) | Listing and interpretation of CD tests performed |
| 12255 | 21 CFR 1271.60(c) | Shipped but not kept in quarantine |
| 12277 | 21 CFR 1271.75(a)(1) | Risk factors, clinical evidence |
| 12290 | 21 CFR 1271.80(d)(1) | Reactive tests--not determined ineligible |